Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous hCG-activated PBMC intrauterine therapy for recurrent implantation failure
IRCT2017081227520N8Phase 2Completed
- Sponsor
- Stem Cell and Regenerative Medicine Institute, Tabriz University of Medical Sciences
- Start
- Oct 2017
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, double-blind trial of human chorionic gonadotropin-activated autologous peripheral blood mononuclear cells in Recurrent Implantation Failure (RIF) (2 arms), sponsored by Stem Cell and Regenerative Medicine Institute, Tabriz University of Medical Sciences. Primary endpoints: Pregnancy rate, Live birth rate and 1 more. Started Oct 2017; status: completed.
02
Drugs
human chorionic gonadotropin-activated autologous peripheral blood mononuclear cells
03
Conditions
Recurrent Implantation Failure (RIF)
Beyond the preview
Go deeper on IRCT2017081227520N8.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2017081227520N8.